Logo.png
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel Therapeutic Assessment
August 12, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel...
CENTOGENElogo.jpg
CENTOGENE Extends Partnership With Takeda
April 14, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
logo-alt.png
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 12, 2021 10:05 ET | PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
Light Chain Bioscience successfully completes Factor VIII mimetic bispecific antibody discovery for Takeda
February 14, 2020 03:00 ET | Light Chain Bioscience - NovImmune SA
GENEVA, Switzerland, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Light Chain Bioscience, a company developing bispecific antibodies with a pipeline focused in immuno-oncology, announced that it has achieved a...
LogicBio-logo-RGB.png
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
January 10, 2020 07:05 ET | LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
LogicBio-logo-RGB.png
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
January 10, 2020 07:00 ET | LogicBio Therapeutics
– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome – – The collaboration agreement grants Takeda an...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
July 16, 2019 13:15 ET | Schall Law
LOS ANGELES, July 16, 2019 (GLOBE NEWSWIRE) --  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
July 09, 2019 11:30 ET | Schall Law
LOS ANGELES, July 09, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
July 02, 2019 11:30 ET | Schall Law
LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda...
breathtec.jpg
Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease
January 21, 2019 07:00 ET | Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...